Complications and treatment of patients with β-thalassemia in France: Results of the national registry

Haematologica

Volumn 95, Issue 5, 2010, Pages 724-729

  Thuret, Isabelle ^a   Pondarré, Corinne ^a,b   Loundou, Anderson ^c   Steschenko, Dominique ^c,d   Girot, Robert ^e   Bachir, Dora ^f   Rose, Christian ^g   Barlogis, Vincent ^a   Donadieu, Jean ^h   de Montalembert, Mariane ⁱ   Hagege, Isabelle ^e   Pegourie, Brigitte ^j   Berger, Claire ^k   Micheau, Marguerite ^l   Bernaudin, Françoise ^m   Leblanc, Thierry ⁿ   Lutz, Laurence ^o   Galactéros, Frédéric ^f   Siméoni, Marie Claude ^c   Badens, Catherine ^a  

^a TIMONE HOSPITAL   (France)

^b Institut d'Hematologie et d'Oncologie Pediatrique   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d CHU NANCY BRABOIS   (France)

^e HÔPITAL TENON   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g HÔPITAL SAINT VINCENT DE PAUL   (France)

^h ARMAND TROUSSEAU HOSPITAL   (France)

ⁱ HÔPITAL NECKER ENFANTS MALADES   (France)

^j HÔPITAL MICHALLON   (France)

^k HÔPITAL NORD   (France)

^l HÔPITAL PELLEGRIN   (France)

^m CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

ⁿ HÔPITAL ROBERT DEBRÉ   (France)

^o HÔPITAL DE HAUTEPIERRE   (France)

more..

Author keywords

thalassemia; Epidemiology; France; National registry

Indexed keywords

DEFERASIROX; DEFEROXAMINE; FERRITIN;

ADULT; ARTICLE; BETA THALASSEMIA; CHELATION THERAPY; CHOLECYSTECTOMY; CROSS-SECTIONAL STUDY; DEVELOPED COUNTRY; DIABETES MELLITUS; FEMALE; FERRITIN BLOOD LEVEL; FRANCE; HEART FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PARENTHOOD; QUESTIONNAIRE; REGISTER; SPLENECTOMY; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; INFANT; IRON OVERLOAD; MALE; MIDDLE AGED; REGISTRIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952378224     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.018051     Document Type: Article

References (18)

1. Badens C, North ML, Lena-Russo D. Betathalassemia in metropolitan France. Presse Med. 2003;32(22):1016-21.
2. Modell B, Khan M, Darlison M, King A, Layton M, Old J, et al. Survival in beta-thalassemia major in the UK: data from the UK thalassemia register. Lancet. 2000;355 (9220):2051-2.
3. Dickerhoff R, Genzel-Boroviczeny O, Kohne E. Haemoglobinopathies and new- born haemoglobinopathy screening in Germany. J Clin Pathol. 2009;62(1):34.
4. Gulbis B, Cotton F, Ferster A, Ketelslegers O, Dresse MF, Rongé-Collard E, et al. Neonatal haemoglobinopathy screening in Belgium. J Clin Pathol. 2009;62(1):49-52.
5. Vogiatzi MG, Macklin EA, Trachtenberg FL, Fung EB, Cheung AM, Vichinsky E, et al. Thalassemia Clinical Research Network. Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America. Br J Haematol. 2009;146(5):546-56.
6. De Sanctis V, Eleftheriou A, Malaventura C; Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia haematologica 2010; 95(5) International Federation (TIF). Pediatr Endocrinol Rev. 2004;2 (Suppl 2):249-55.
7. Shalitin S, Carmi D, Weintrob N, Phillip M, Miskin H, Kornreich L, et al. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. Eur J Haematol. 2005;74(2):93-100.
8. Skordis N, Petrikkos L, Toumba M, Hadjigavriel M, Sitarou M, Kolnakou A, et al. Update on fertility in thalassaemia major. Pediatr Endocrinol Rev. 2004;2 (Suppl 2):296-302.
9. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR; Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America. Blood. 2004;104(1):34-9.
10. Borgna-Pignatti C. Modern treatment of thalassaemia intermedia. Br J Haematol. 2007;138(3):291-304.
11. Cario H, Stahnke K, Sander S, Kohne E. Epidemiological situation and treatment of patients with thalassemia major in Germany: results of the German multicenter beta-thalassemia study. Ann Hematol. 2000;79(1):7-12
12. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006;107(9):3733-7.
13. Lucarelli G, Galimberti M, Polchi P, Angelucci E, Baronciani D, Giardini C, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990; 322(7):417-21.
14. Locatelli F, Rocha V, Reed W, Bernaudin F, Ertem M, Grafakos S, et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood. 2003;101(6):2137-43.
15. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008; 10(1):42.
16. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferriprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002;360(9332): 516-20.
17. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738-44.
18. Telfer P, Coen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica. 2006; 91(9):1187-92.